Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia

Schizophrenia Bulletin

Volumn 33, Issue 5, 2007, Pages 1120-1130

  Buchanan, Robert W ^a   Freedman, Robert ^b   Javitt, Daniel C ^c   Abi Dargham, Anissa ^d   Lieberman, Jeffrey A ^e  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^e Columbia University ^*

Author keywords

Cognitive impairments; Dopamine; Glutamate; Nicotinic receptors

Indexed keywords

10,11 DIHYDROXY 5,6,6A,7,8,12B HEXAHYDROBENZO[A]PHENANTHRIDINE; 3 [(2,4 DIMETHOXY)BENZYLIDENE]ANABASEINE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; CYCLOSERINE; DAR 0100; DEXTRO ALANINE; DEXTRO SERINE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; EGLUMETAD; GADOLINIUM; GALANTAMINE; GLUTAMIC ACID; GLYCINE; GLYCYLDODECYLAMIDE; KETAMINE; N [3 (4 FLUOROPHENYL) 3 (4 PHENYLPHENOXY)PROPYOL]SARCOSINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; ORG 24598; PHENCYCLIDINE; RISPERIDONE; RIVASTIGMINE; SARCOSINE; SSR 504734; TROPISETRON; UNCLASSIFIED DRUG;

CHOLINERGIC ACTIVITY; CLINICAL TRIAL; COGNITIVE DEFECT; DOPAMINERGIC ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DRUG DESIGN; HUMANS; PROGRAM DEVELOPMENT; RECEPTORS, AMPA; RECEPTORS, DOPAMINE; RECEPTORS, GLUTAMATE; RECEPTORS, MUSCARINIC; RECEPTORS, NICOTINIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 34548321168     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbm083     Document Type: Review

References (144)

1. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004;72:29-39.
2. Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry. 2004;55:1013-1022.
3. Woodward ND, Purdon SE, Meltzer HY, Zaid DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol. 2005;8:457-472.
4. Keefe RSE, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry. 2007;64:633-647.
5. Geyer M, Tamminga CA. Measurement and treatment research to improve cognition in schizophrenia: neuropharmacological aspects. Psychopharmacology (Berl). 2004;174:1-2.
6. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry. 2000;157:4-15.
7. Broocks A, Little JT, Mrtin A, et al. The influence of ondasetron and m-chlorophenylpiperazine on scopolamineinduced cognitive, behavioral, and physiological responses in young healthy controls. Biol Psychiatry. 1998;43:408-416.
8. Furey ML, Pietrini P, Haxby JV. Cholinergic enhancement and increased selectivity of perceptual processing during working memory. Science. 2000;290:2315-2319.
9. Vitiello B, Martin A, Hill J, et al. Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans. Neuropharmacology. 1997;16:15-24.
10. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry. 2000;48:381-388.
11. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry. 2001;158:918-925.
12. Deng C, Huang XF. Decreased density of muscarinic receptors in the superior temporal gyrus in schizophrenia. J Neurosci Res. 2005;81:883-890.
13. Freedman R, Hall M, Adler LE, Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry. 1995;38:22-33.
14. Guan ZZ, Zhang X, Blennow K, Nordberg A. Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport. 1999;10:1779-1782.
15. Breese CR, Lee MJ, Adams CE, et al. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology. 2000;23:351-364.
16. Raedler TJ, Knable MB, Jones DW, et al. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry. 2003;160:118-127.
17. Adler LE, Olincy A, Waldo M, et al. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull. 1998;24:189-202.
18. Depatie L, O'Driscoll G, Holahan A-L, et al. Nicotine and behavioral markers of risk for schizophrenia: a doubleblind, placebo-controlled, cross-over study. Neuropsychopharmacology. 2002;27:1056-1070.
19. Avila MT, Sherr JD, Hong E, Myers CS, Thaker GK. Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia. Neuropsychopharmacology. 2003;28:2184-2191.
20. Harris JG, Kongs S, Allensworth DA, Sullivan B, Zerbe G, Freedman R. Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology. 2004;29:1378-1385.
21. Myers CS, Robles O, Kakoyannis AN, et al. Nicotine improves delayed recognition in schizophrenic patients. Psychopharmacology (Berl). 2004;174:334-340.
22. Sacco KA, Termine A, Seyal A, et al. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry. 2005;62:649-659.
23. Baldeweg T, Wong D, Stephan KE. Nicotinic modulation of human auditory sensory memory: evidence from mismatch negativity potentials. Int J Psychophysiol. 2006;59:49-58.
24. George TP, Termine A, Sacco KA, et al. A preliminary study of the effects of cigarette smoking on prepulse inhibition in schizophrenia: involvement of nicotinic receptor mechanisms. Schizophr Res. 2006;87:307-315.
25. Smith RC, Warner-Cohen J, Matute M, et al. Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacology. 2006;31:637-643.
26. Walker DP, Wishka DG, Piotrowski DW, et al. Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as alpha7 nicotinic acetylcholine receptor agonists. Bioorg Med Chem. 2006;14:8219-8248.
27. Kem WR, Mahnir VM, Prokai L, et al. Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy) benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration. Mol Pharmacology. 2004;65:56-67.
28. De Fiebre CM, Meyer EM, Henry JC, Muraskin SI, Kem WR, Papke RL. Characterization of a series of anabaseinederived compounds reveals that the 3-(4)-dimethylaminocinnamylidine derivative is a selective agonist at neuronal nicotinic alpha-7/125 I-alpha-bungarotoxin receptor subtypes. Mol Pharmacology. 1995;47:164-171.
29. Olincy A, Young DA, Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry. 1997;42:1-5.
30. Jacobsen LK, D'Souza DC, Mencl WE, Pugh KR, Skudlarski P, Krystal JH. Nicotine effects on brain function and functional connectivity in schizophrenia. Biol Psychiatry. 2004;55:850-858.
31. Smith RC, Singh A, Infante M, Khandat A, Kloos A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology. 2002;27:479-497.
32. George T, Vessicchio J, Termine A, et al. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology. 2002;26:75-85.
33. Briggs CA, McKenna DG, Piattoni-Kaplan M. Human alpha-7 nicotinic acetylcholine receptor responses to novel ligands. Neuropharmacology. 1995;34:583-590.
34. Stokes C, Papke JK, Horenstein NA, Kem WR, McCormack TJ, Papke RL. The structural basis for GTS-21 selectivity between human and rat nicotinic alpha7 receptors. Mol Pharmacology. 2004;66:14-24.
35. Olincy A, Harris JG, Johnson LL, et al. Proof-of-concept trial of an α7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry. 2006;63:630-638.
36. Gold JM, Queern C, Iannone VN, Buchanan RW. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity. Am J Psychiatry. 1999;156:1944-1950.
37. Stevens KE, Kem WR, Mahnir VM, Freedman R. Selective alpha-7 nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology (Berl). 1998;136:320-327.
38. Koike K, Hashimoto K, Takai N, et al. Tropisetron improves deficits in auditory sensory P50 suppression in schizophrenic patients. Schizophr Res. 2005;76:67-72.
39. Chung YC, Li Z, Dai J, Meltzer HY, Ichikawa J. Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism. Brain Res. 2004;1023:54-63.
40. Adler LE, Olincy A, Cawthra E, et al. The varied effects of atypical medications on P50 auditory gating in schizophrenic patients. Am J Psychiatry. 2004;161:1822-1828.
41. Simosky JK, Stevens KE, Adler LE, Freedman R. Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacology (Berl). 2003;165:386-396.
42. George TP, Serynak MJ, Ziedonis DM, Woods SW. Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry. 1997;56:344-346.
43. McEvoy JP, Freudenreich O, Wilson W. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry. 1999;46:125-129.
44. Ferreri F, Agbokou C, Gautheir S. Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. J Psychiatry Neurosci. 2006;31:369-376.
45. Buchanan RW, Summerfelt A, Tek C, Gold J. An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res. 2003;59:29-33.
46. Stryjer R, Strous RD, Bar F, et al. Donepezil augmentation of clozapine monotherapy in schizophrenia patients: A double blind cross-over study. Hum Psychopharmacol. 2004;19:343-346.
47. Erickson SK, Schwarzkopf SB, Palumbo D, Badgley-Fleeman J, Smirnov AM, Light GA. Efficacy and tolerability of low-dose donepezil in schizophrenia. Clin Neuropharmacol. 2005;28:179-184.
48. Friedman JI, Adler DN, Howanitz E, et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry. 2002;51:349-357.
49. Freudenreich O, Herz L,Deckersbach T, et al. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl). 2005;181:358-363.
50. Fagerlund B, Soholm B, Fink-Jensen A, Lublin H, Glenthoj BY. Effects of donepezil adjunctive treatment of ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study. Clin Neuropharmacol. 2007;30:3-12.
51. Keefe RSE, Malhotra AK, Meltzer H, Kane JM, Buchanan RW, Murthy A, Sovel M, Li C, Goldman R. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo effects in a 12-week, randomized, double-blind, placebo-controlled trial. Clin Neuropsychopharmacology. In press.
52. Lenzi A, Maltinti E, Poggi E, Fabrizio L, Coli E. Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia. Clin Neuropharmacol. 2003;26:317-321.
53. Mendelsohn E, Rosenthal M, Bohiri Y, Werber E, Kotler M, Strous RD. Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living. Int Clin Psychopharmacol. 2004;19:319-324.
54. Sharma T, Reed C, Aasen I, Kumari V. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. Schizophr Res. 2006;85:73-83.
55. Schubert MX, Young KA, Hicks PB. Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry. 2006;60:530-533.
56. Lee S-W, Lee J-G, Lee B-J, Kim YH. A 12-week, doubleblind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Int Clin Psychopharmacol. 2007;22:63-68.
57. Buchanan RW, Conley RR, Dickinson D, Nelson MW, Gold JM, McMahon RP. Galantamine for the treatment of cognitive impairments in patients with schizophrenia. Schizophr Bull. 2007;33:424.
58. Maelicke A, Albuquerque EX. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol. 2000;393:165-170.
59. Samochocki M, Höffle A, Fehrenbacher A, et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmcol Exp Ther. 2003;305:1024-1036.
60. Dajas-Bailador FA, Heimala K, Wonnacott S. The allosteric potentiation of nicotinic acetylcholine receptors by galantamine is transduced into cellular responses in neurons: Ca2+ signals and neurotransmitter release. Mol Pharmacol. 2003;64:1217-1226.
61. Schilström B, Ivanov VB, Wiker C, Svensson TH. Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacology. 2007;32:43-53.
62. 25-35 I.c.v.-injected mice: involvement of dopaminergic systems. Neuropsychopharmacology. 2006;1-11.
63. Meltzer HY, Stahl SM. The dopamine hypothesis of schizophrenia: a review. Schizophr Bull. 1976;2:19-76.
64. Carlsson A. Does dopamine play a role in schizophrenia? Psychol Med. 1977;7:583-597.
65. Crow TJ. Positive and negative schizophrenia symptoms and the role of dopamine. Br J Psychiatry. 1981;139:251.
66. Seeman P, Bzowej NH, Guan HC, et al. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Hunington's diseases. Neuropsychopharmacology. 1987;1:5-15.
67. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987;44:660-669.
68. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991;148:1474-1486.
69. Carlsson ML, Carlsson A, Nilsson M. Schizophrenia: from dopamine to glutamate and back. Curr Med Chem. 2004;11:267-277.
70. Pycock CJ, Kerwin RW, Carter CJ. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature. 1980;286:74-77.
71. Carlsson M, Carlsson A. Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schizophr Bull. 1990;16:425-432.
72. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321-330.
73. Goldberg TE, Patterson KJ, Taqqu Y, Wilder K. Capacity limitations in short-term memory in schizophrenia: tests of competing hypotheses. Psychol Med. 1998;28:665-673.
74. Barch DM, Sheline YI, Csernansky JG, Snyder AZ. Working memory and prefrontal cortex dysfunction: specificity to schizophrenia compared with major depression. Biol Psychiatry. 2003;53:376-384.
75. Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl). 1987;91:415-433.
76. Jaskiw GE, Popli AP. A meta-analysis of the response to chronic L-dopa in patients with schizophrenia: therapeutic and heuristic implications. Psychopharmacology (Berl). 2004;171:365-374.
77. Neve KA, Neve RL. The Dopamine Receptors. Totowa, NJ: Humana Press; 1997.
78. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev. 1998;78:189.
79. Huang X, Lawler CP, Lewis MM, Nichols DE, Mailman RB. D1 dopamine receptors. Int Rev Neurobiol. 2001;48:65.
80. De Keyser J, Ebinger G, Vauquelin G. Evidence for a widespread dopaminergic innervation of the human cerebral neocortex. Neurosci Lett. 1989;104:281-285.
81. Hall H, Sedvall G, Magnusson O, Kopp J, Halldin C, Farde L. Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology. 1994;11:245-256.
82. Dawson TM, McCabe RT, Stensaas SS, Wamsley JK. Autoradiographic evidence of [3H]SCH23390 binding sites in human prefrontal cortex (Brodmann's area 9). J Neurochem. 1987;49:789-796.
83. Lidow MS, Goldman-Rakic PS, Rakic P, Gallager DW. Autoradiographic comparison of D1-specific binding of [3H]SCH39166 and [3H]SCH23390 in the primate cerebral cortex. Brain Res. 1990;537:349-354.
84. Yang CR, Seamans JK. Dopamine D1 receptor actions in layers V-VI rat prefrontal cortex neurons in vitro: modulation of dendritic-somatic signal integration. J Neurosci. 1996;16:1922-1935.
85. Seamans JK, Gorelova N, Durstewitz D, Yang CR. Bidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons. J Neurosci. 2001;21:3628-3638.
86. Knable MB, Weinberger DR. Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol. 1997;11:123-131.
87. Akil M, Pierri JN, Whitehead RE, et al. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry. 1999;156:1580-1589.
88. Goldman-Rakic PS, Muly EC3rd, Williams GV. . D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev. 2000;31:295-301.
89. Abi-Dargham A, Mawlawi O, Lombardo I, et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci. 2002;22:3708-3719.
90. Arnsten AF, Cai JX, Murphy BL, Goldman-Rakic PS. Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology (Berl). 1994;116:143-151.
91. Sawaguchi T, Goldman-Rakic PS. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science. 1991;251:947-950.
92. Castner SA, Williams GV, Goldman-Rakic PS. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science. 2000;287:2020-2022.
93. Castner SA, Goldman-Rakic PS. Enhancement of working memory in aged monkeys by a sensitizing regimen of dopamine D1 receptor stimulation. J Neurosci. 2004;24:1446-1450.
94. Lovenberg TW, Brewster WK, Mottola DM, et al. Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist. Eur J Pharmacol. 1989;166:111-113.
95. Brewster WK, Nichols DE, Riggs RM, et al. trans-10,11-dihydroxy-5,6,6a,7, 8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. J Med Chem. 1990;33:1756-1764.
96. Mottola DM, Brewster WK, Cook LL, NIchols DE, Mailman RB. Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist. J Pharmacol Exp Ther. 1992;262:383-393.
97. Mottola DM, Laiter S, Watts VJ, et al. Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping. J Med Chem. 1996;39:285-296.
98. Darney KJ Jr, Lewis MH, Brewster WK, Nichols DE, Mailman RB. Behavioral effects in the rat of dihydrexidine, a high-potency, full-efficacy D1 dopamine receptor agonist. Neuropsychopharmacology. 1991;5:187-195.
99. Kohli JD, Horn PT, Glock D, Brewster WK, Nichols DE. Dihydrexidine: a new potent peripheral dopamine D1 receptor agonist. Eur J Pharmacol. 1993;235:31-35.
100. Mottola DM, Kilts JD, Lewis MM, et al. Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther. 2002;301:1166-1178.
101. Kilts JD, Connery HS, Arrington EG, et al. Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. J Pharmacol Exp Ther. 2002;301:1179-1189.
102. Knoerzer TA, Nichols DE, Brewster WK, Watts VJ, Mottola D, Mailman RB. Dopaminergic benzo[a]phenanthridines: resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist. J Med Chem. 1994;37:2453-2460.
103. Blanchet PJ, Fang J, Gillespie M, et al. Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkin's disease. Clin Neuropharmacol. 1998;21:339-343.
104. George MS, Molnar CE, Grenesko EL, et al. A single 20mg dose of dihydrexidine (DAR-0100), a full dopamine D (1) agonist, is safe and tolerated in patients with schizophrenia. Schizophr Res. 2007;93:42-50.
105. Cotman CW, Monaghan DT. Chemistry and anatomy of excitatory amino acid systems. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:197-210.
106. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301-1308.
107. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 1998;281:1349-1352.
108. Krystal JH, Abi-Saab W, Perry E, et al. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl). 2004;179:303-309.
109. Goff DC, Herz L, Posever T, et al. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl). 2005;179:144-150.
110. Heresco-Levy U, Javitt DC. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res. 2004;66:89-96.
111. Javitt DC, Duncan L, Balla A, Sershen H. Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Mol Psychiatry. 2005;10:275-287.
112. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP.Amelioration of negative symptoms in schizophrenia by glycine. Am. J Psychiatry. 1994;151:1234-1236.
113. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry. 1999;56:29-36.
114. Javitt DC, Silipo G, Cienfuegos A, et al. Adjunctive highdose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol. 2001;4:385-392.
115. Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry. 2004;55:165-171.
116. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 1998;44:1081-1089.
117. Heresco-Levy U, Javitt DC, Ebstein R, et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry. 2005;57:577-585.
118. Tsai GE, Yang P, Chang YC, Chong MY. D-alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 2006;59:230-234.
119. Buchanan RW, Javitt DC, Marder SR, et al. The cognitive and negative symptoms in schizophrenia trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry.In press.
120. Woods SW, Thomas L, Tully E, et al. Effects of oral glycine in the schizophrenia prodrome. Schizophr Res. 2004;70:(Suppl):79.
121. Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 2004;55:452-456.
122. Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry. 2005;62:1196-1204.
123. Lane HY, Huang CL, Wu PL, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry. 2006;60:645-649.
124. Javitt DC, Sershen H, Hashim A, Lajtha A. Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacology. 1997;17:202-204.
125. Atkinson BN, Bell SC, De Vivo M, et al. ALX 5407; a potent, selective inhibitor of the hGlyT1 glycine transporter. Mol Pharmacol. 2001;60:1414-1420.
126. Aubrey KR, Vandenberg RJ. N[3-(4′-fluorophenyl)-3-(4′- phenylphenoxy)propyl] sarcosine (NFPS) is a selective persistent inhibitor of glycine transport. Br J Pharmacol. 2001;134:1429-1436.
127. Herdon HJ, Godfrey FM, Brown AM, Coulton S, Evans JR, Cairns WJ. Pharmacological assessment of the role of te glycine transporter GlyT-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes. Neuropharmacology. 2001;41:88-96.
128. Harsing LG Jr, Gacsalyi I, Szabo G, et al. The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study. Pharmacol Biochem Behav. 2003;74:811-825.
129. Brown A, Carlyle I, Clark J, et al. Discovery and SAR of org 24598-a selective glycine uptake inhibitor. Bioorg Med Chem Lett. 2001;11:2007-2009.
130. Depoortere R, Dargazanli G, Estenne-Bouhtou G, et al. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology. 2005;30:1963-1985.
131. Javitt DC, Balla A, Sershen H, Lajtha A. A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Biol Psychiatry. 1999;45:668-679.
132. Bergeron R, Meyer TM, Coyle JT, Greene RW. Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci U S A. 1998;95:15730-15734.
133. Chen L, Muhlhauser M, Yang CR. Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J Neurophysiol. 2003;89:691-703.
134. Kinney GG, Sur C, Burno M, et al. The glycine transporter type 1 inhibitor N-[3-(4′-fluorophenyl)-3-(4′-phenylphenoxy)-propyl] sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J Neurosci. 2003;23:7586-7591.
135. Le Pen G, Kew J, Alberati D, Borroni E, Heitz MP, Moreau JL. Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal-lesioned rats: reversal by glycine and a glycine transporter inhibitor. Biol Psychiatry. 2003;54:1162-1170.
136. Javitt DC, Balla A, Burch S, Suckow R, Xie S, Sershen H. Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists. Neuropsychopharmacology. 2004;29:300-7.
137. Hampson RE, Rogers G, Lynch G, Deadwyler SA. Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to- sample performance. J Neurosci. 1998;8:2740-2747.
138. Porrino LJ, Daunais JB, Rogers GA, Hampson RE, Deadwyler SA. Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates. PLoS Biol. 2005;3:e299.
139. Johnson SA, Luu NT, Herbst TA, et al. Synergistic interactions between ampakines and antipsychotic drugs. J Pharmacol Exp Ther. 1999;289:392-397.
140. Goff DC, Leahy L, Berman I, et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol. 2001;21:484-487.
141. Goff DC, Lamberti JS, Leon AC, et al. A placebo-controlled add-on trial of ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology. 2007;In press.
142. Marenco S, Egan MF, Goldberg TE, et al. Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series. Schizophr Res. 2002;57:221-226.
143. Marino MJ, Conn PJ. Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors. Curr Opin Pharmacol. 2006;6:98-102.
144. Schoepp DD. New directions in the treatment of schizophrenia: modulators of mGlu2 and/or mGlu3 receptors. Neuropsychopharmacology. 2006;31:S26.